{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-119946","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2023-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.199271+00:00","generated_at":"2026-06-07T23:12:32.365913+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Marker Therapeutics terminates Interim CFO; CEO assumes principal financial officer role","bullets":["On Nov 17, 2023, Marker terminated Danforth Advisors consulting agreement, effective Jan 16, 2024.","Eliot M. Lurier ceased as Interim CFO and Principal Financial and Accounting Officer immediately.","CEO Juan Vera appointed as Principal Financial and Accounting Officer effective Nov 17, 2023.","No replacement CFO has been announced; CEO will handle financial officer duties."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-119946","json":"https://secwatch.observer/filing/0001104659-23-119946.json","markdown":"https://secwatch.observer/filing/0001104659-23-119946.md","text":"https://secwatch.observer/filing/0001104659-23-119946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923119946/0001104659-23-119946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923119946/tm2330976d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T23:12:32.365913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13879c3bf5","claim":"Eliot M. Lurier departed as Interim Chief Financial Officer and Principal Financial and Accounting Officer at Marker Therapeutics, Inc..","evidence_excerpt":"On November 17, 2023, Mr. Lurier ceased serving as the Company’s Interim Chief Financial Officer and Principal Financial and Accounting Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923119946/0001104659-23-119946-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Interim Chief Financial Officer and Principal Financial and Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"830d1d0ea5","claim":"Juan Vera was appointed as Principal Financial and Accounting Officer at Marker Therapeutics, Inc..","evidence_excerpt":"Juan Vera, the Company’s President and Chief Executive Officer, was appointed as the Company’s Principal Financial and Accounting Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923119946/0001104659-23-119946-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Financial and Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}